Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01501487 · ClinicalTrials.gov registry record · Phase 4
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
A Phase 4 study, sponsored by Agendia.
- Completed
- Registry status
- Phase 4
- Development phase
- 226
- Enrollment target
NCT01501487: Completed Phase 4 study, sponsored by Agendia.
NCT01501487 is a Phase 4 study that has completed, run by Agendia. The registered enrollment target is 226 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01501487, a Phase 4 study, has completed, sponsored by Agendia.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 226 participants
- Enrollment target
Study Summary
Genomics assays that measure specific gene expression patterns in a patient's primary tumor have become important prognostic tools for breast cancer patients. This study is designed to test the ability of MammaPrint® in combination with TargetPrint®, BluePrint®, and TheraPrint®, as well as traditional pathologic and clinical prognostic factors, to predict responsiveness to neo-adjuvant chemotherapy in patients with locally advanced breast cancer (LABC).
Interventions
- DRUG TAC chemotherapy
- DRUG TC chemotherapy
- DRUG Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy
- DRUG TCH chemotherapy
- DRUG T + trastuzumab followed by CEF + trastuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2011-10 |
| Est. Completion | 2017-06 |
| Phase | Phase 4 |
What the finished NCT01501487 record still lists
NCT01501487 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 5 interventions - of which TAC chemotherapy is the first listed.
NCT01501487 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01501487 about?
NCT01501487 is a clinical study titled "MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I". Genomics assays that measure specific gene expression patterns in a patient's primary tumor have become important prognostic tools for breast cancer patients. This study is designed to test the ability of MammaPrint® in combination with TargetPrint®, BluePrint®, and TheraPrint®, as well as tradition...
What is the current status of trial NCT01501487?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 226 participants. The study started on 2011-10. Estimated completion is 2017-06.
What interventions are being tested in trial NCT01501487?
The interventions under investigation include: TAC chemotherapy (DRUG), TC chemotherapy (DRUG), Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy (DRUG), TCH chemotherapy (DRUG), T + trastuzumab followed by CEF + trastuzumab (DRUG).
Who is sponsoring clinical trial NCT01501487?
This trial is sponsored by Agendia, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01501487's enrollment target sits among peer trials
226 376th of 2000 higher than 1,622 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia